<DOC>
	<DOCNO>NCT00430833</DOCNO>
	<brief_summary>The primary hypothesis study treatment AT1-R antagonist patient nonobstructive form HCM first save , second cause regression myocardial hypertrophy .</brief_summary>
	<brief_title>CHANCE - Candesartan Hypertrophic Cardiomyopathy</brief_title>
	<detailed_description>Patients randomly assign 1:1 ratio either candesartan ( target dose 32 mg daily ) match placebo . The initial dose study drug 8 mg daily . Study drug dose double tolerated every 2 week aim target dose 32 mg daily . Monitoring blood pressure , serum creatinine , serum potassium pressure gradient LV outflow tract perform dose increase . Patients observe clinically 3 , 6 , 12 month maintenance dose reach . Exercise tolerance assess bicycle ergometry , presence malignant arrhythmias Holter monitoring , extent LV hypertrophy 2-dimensional echocardiography , LV outflow tract pressure gradient Doppler echocardiography baseline 12-month follow-up .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>HCM define basis echocardiographic criterion show nondilated , hypertrophied leave ventricle ( wall thickness &gt; 15 mm ) absence know cause LV hypertrophy hypertension valvular disease Hypertrophic obstructive cardiomyopathy define presence rest gradient leave ventricular outflow tract ³30 mmHg righ ventricular outflow tract ³15 mmHg Doppler echocardiography ; Atrial fibrillation ; Treatment ACE inhibitor AT1R antagonist time past ; Contraindications AT1R antagonists ; Coronary artery disease , renal failure , hepatic disorder serious intercurrent illness limit survival ; Poor echocardiographic image quality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>